Drugs / FPI-1175
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03746431 | Jan 2019 → Dec 2025 | adrenal cortex carcinoma, cervical cancer, endometrial cancer, head and neck squamous cell carcinoma +3 | Fusion Pharmaceuticals Inc. | Terminated | Met primary Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-06-14 | Fusion Pharmaceuticals Inc. | Impact of Pre-Administration of Anti-IGF-1R Antibody FPI-1175 on the Dosimetry, Tumor Uptake, and Pharmacokinetics of the IGF-1R Targeted Theranostic Imaging Agent [111In]-FPI-1547 in Patients with Solid Tumors fusionpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FPI-1175 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03746431 ↗ |
| Modality | Monoclonal antibody | “an insulin-like growth factor-1 receptor (IGF-1R)-targeting humanized monoclonal antibody” NCT03746431 ↗ |